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Pre-symptomaticThe mucopolysaccharidoses (MPS), a group of rare genetic disorders caused by defects in glycosaminoglycan
(GAG) catabolism, are progressive,multi-systemic diseaseswith a highburdenofmorbidity. Enzyme replacement
therapy (ERT) is available for MPS I, II, and VI, andmay improve walking ability, endurance, and pulmonary func-
tion as evidenced by data from pivotal trials and extension studies. Despite these demonstrable benefits, cardiac
valve disease, joint disease, and skeletal disease, all of which cause significantmorbidity, do not generally improve
with ERT if pathological changes are already established. Airway disease improves, but usually does not normalize.
These limitations can be well understood by considering the varied functions of GAG in the body. Disruption of
GAG catabolism has far-reaching effects due to the triggering of secondary pathogenic cascades. It appears that
many of the consequences of these secondary pathogenic events, while they may improve on treatment, cannot
be fully corrected even with long-term exposure to enzyme, thereby supporting the treatment of patients with
MPS before the onset of clinical disease. This review examines the data from clinical trials and other studies in
human patients to explore the limits of ERT as currently used, then discusses the pathophysiology, fetal tissue
studies, animal studies, and sibling reports to explore the question of how early to treat an MPS patient with a
firmdiagnosis. The review is followedby an expert opinion on the rationale for and the benefits of early treatment.
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The mucopolysaccharidoses (MPS) are a group of rare progressive
genetic disorders characterized by defects in glycosaminoglycan
(GAG) catabolism, leading to the accumulation of partially degraded
GAG within lysosomes [1]. Each of the eleven MPS is caused by a defi-
ciency in the activity of a single, specific lysosomal enzyme required
for GAG degradation. The progressive accumulation of GAG results in
cellular and organ damage. Clinical manifestations are evident in nearly
every system, including respiratory, cardiopulmonary, musculoskeletal,
gastrointestinal, and neurological, causing significant morbidity and
early mortality in the severe forms of these disorders. All of the MPS
are inherited in an autosomal recessive pattern with the exception of
MPS II (OMIM 309900). MPS II is an X-linked recessive disorder that
generally affects only males, although rare, female patients with MPS
II are reported [2,3].
The MPS are heterogeneous disorders, and patients present with a
wide spectrumof clinical severity [1]. MostMPS patients appear normal
at birth, but patients with severe phenotypes typically develop clinical
signs and symptoms before the age of 2 to 4 years and can die before
the age of 10 years. Patients with the severe forms of MPS I, II, and VII,
and allMPS III patients, will also develop cognitive impairment. Patients
with an attenuated phenotype can develop all of the somatic signs and
symptoms seen in the severe phenotype, but never develop cognitive
impairment. The onset of somatic symptoms is generally later and the
disease progression slower. Such patients may live well into adulthood.
While the cognitive involvement is the hallmark of the severe pheno-
type in MPS I, II, III, and VII, it is often difficult to determine whether
or not a patient is experiencing cognitive decline until an age at which
somatic disease is well established. Young patients with MPS may
thus have an indeterminate phenotype.
Enzyme replacement therapy (ERT) via intravenous (IV) infusion of
recombinant human enzyme is available for MPS I, II and VI in the
United States, Europe, and over 40 countries worldwide. The benefits
of ERT may include improvements in joint mobility, walking ability,
and pulmonary and respiratory functions; reduction in liver and spleen
volumes; and reduction in urinary GAG excretion [4–12]. No evidence
exists to suggest that intravenously administered recombinant enzyme
crosses the blood–brain barrier at the labeled doses, and clinical obser-
vation has not supported neurocognitive benefit for patients with se-
vere MPS I or severe MPS II [13,14]. Although ERT has been approved
for MPS I, the current recommended treatment for the severe form of
MPS I, Hurler syndrome, is hematopoietic stem cell transplantation
(HSCT), which has been associated with neurocognitive stabilization
[15,16]. ERT has been used for patients with Hurler syndrome prior to
HSCT and until engraftment occurs; ERT is well tolerated and may sig-
nificantly improve the pre-transplant condition in selected patients
[17–19]. A recent expert consensus panel noted that Hurler syndrome
patients who are referred for HSCT may benefit from ERT before HSCT,
as this can improve their clinical condition, but recommended that ini-
tiating ERT should not delay the transplant [16]. Surprisingly, ERT given
with HSCT has been associatedwith better cognitive outcomes inHurler
syndrome [20]. HSCT is not recommended for patients with the severe
form of MPS II or MPS III, since previous reports have found no evidence
of neurocognitive stabilization [21,22].
In the pivotal ERT trials for MPS I, II, and VI, only patients 5 years of
age and older were enrolled [6,7,12]. Younger patients were excluded
because of their inability to reliably perform the primary efficacy end-
points, such as the 6-minute walk test (6MWT), 12-minute walk test
(12MWT), 3-minute stair climb, and forced vital capacity (FVC) testing[17,18,23]. Only one clinical study of ERT in patients under the age of
5 years with MPS I has been published [5]. Reduction in hepatomegaly,
improvements in sleep apnea, and a reduction in the percentage of pa-
tients displaying left ventricular hypertrophy were observed. No new
safety concerns were seen [5]. Clinical trial data for patients under
5 years of age are lacking for MPS II and VI, although a safety study in-
cluding patients under the age of 5 years has been completed for MPS
II [23]. In that study (NCT00607386), idursulfase (Elaprase®, Shire
Human Genetic Therapies, Inc., Lexington, MA, USA) treatment was as-
sociated with decreases in urinary GAG (uGAG) levels, liver size, and
spleen volume. The safety profile was similar to that observed in previ-
ous clinical studies with patients over the age of 5 years, with almost all
adverse reactions being infusion-related reactions (IRRs). No new safety
concernswere seen in this young cohort. Traditionalmeasures of effica-
cy, such as 6MWTor FVC testing, were not conducted as the enrolled pa-
tients were too young to comply.
The paucity of clinical trial data in children under 5 years old, and
particularly the lack of efficacy data, has resulted in some physicians
and reimbursement agencies failing to support treatment for MPS I, II
and VI patients in this age group. This review will examine the benefits
and limitations of ERTwhen used in older patients with established dis-
ease as reported in published studies, then correlate those findings with
what is known about the pathophysiology of the MPS. Finally, we offer
an expert opinion about the use of ERT in MPS patients under 5 years
of age.
2. Enzyme replacement therapy formucopolysaccharidosis I, II andVI
2.1. Pivotal trial and extension data
The efficacy and safety of ERT with laronidase (Aldurazyme®,
BioMarin/GenzymeLLC, Cambridge,MA,USA), idursulfase, and galsulfase
(Naglazyme®, BioMarin Pharmaceutical Inc., Novato, CA, USA) for MPS I,
II, and VI, respectively, have been established in phase III or II/III clinical
trials and open-label extension studies [4,6,7,10,12]. Liver and spleen vol-
umes, when assessed, and uGAG levels were statistically significantly de-
creased in the treated groups compared with placebo across all three
compounds in the double-blind phases, and these gainsweremaintained
or increased throughout the open label extensions [4,6,7,10,12]. Statisti-
cally significant improvements in mobility as assessed by the 6MWT
(laronidase, idursulfase) and 12MWT (galsulfase) were seen in the
pivotal trials [6,7,12]. In the laronidase open-label extension study, 78%
(31/40) of patients showed either further improvement or stabilization
in the 6MWT distance at the final assessment, while the remaining 22%
(9/40) of patients showed declines [4]. In the idursulfase open-label ex-
tension study, themean increase in 6MWTdistance seen inweekly treat-
ed patients was maintained [10]. The galsulfase open-label study
demonstrated continued increases in overall 12MWT distance through
the end of the open-label extension study [7]. Pulmonary function as
assessed by percent predicted FVC (%FVC) was significantly increased
in the double-blind trial of laronidase, but declined at a very slow rate
during the open-label study (0.78 percentage points per year) [4,6]. For
MPS II, weekly infusions of idursulfase did not result in significant im-
provement in %FVC in the double-blind trial [10,12]. In the trial of
galsulfase for MPS VI, FVC did not significantly improve for treated pa-
tients during either the double-blind or extension portions [9]. A sleep
study evaluation was performed only in the laronidase trial, and the
mean apnea/hypopnea index (AHI) did not decrease significantly with
treatment in the intent-to-treat analysis of the double-blind trial. Howev-
er, the AHI significantly decreased by 6.0 events per hour of sleep among
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these gains were slightly furthered during the extension period [6]. Sta-
tistically significant improvements in elbow joint mobility were seen in
the idursulfase double-blind trial but not in the extension study
[4,10,12]. Significant improvements in shoulder mobility were seen for
patients with the greatest baseline impairment in the laronidase
double-blind trial and extension study, as well as in the idursulfase ex-
tension study [6,7,12].
ERTwas generallywell tolerated [4,6,7,10,12]. Themost common ad-
verse events in the clinical trials and extension studies were infusion-
related reactions (IRRs) and were successfully managed by slowing or
stopping the infusion and/or premedication with antihistamines or ste-
roids. Serious or potentially life-threatening IRRs were uncommon but
were seen in three patients treated with idursulfase [12] and two pa-
tients treated with laronidase [6]. The prescribing information for
laronidase and idursulfase carries a black-box warning that life-
threatening anaphylactic reactions have been observed in somepatients
during infusions; therefore, appropriate medical support should be
readily available during treatment [24,25]. ForMPS II, the risk of IRRs ap-
pears to be greatest in thefirst 6 months of treatment, while the onset of
a first IRR has been reported to be much more variable for MPS I and VI,
occurring as late as week 134 of treatment for MPS I and week 84 for
MPS VI [26]. However, in postmarketing reports, patients treated with
idursulfase have experienced anaphylactic reactions up to several
years after initiating treatment [25]. The prescribing information for all
three products contains warnings about the risks of anaphylaxis and al-
lergic reactions and recommendations against administering ERT to pa-
tients with acute respiratory complications [24,25,27]. Patients with
compromised respiratory function or acute respiratory disease may be
at risk of serious acute exacerbation of their respiratory compromise
due to IRRs, and these patients require additional monitoring.
2.2. Limitations of enzyme replacement therapy
2.2.1. Cardiac valve disease
ERTdoes not appear to improve cardiac valve disease for themajority
of patients with valve disease present at the start of ERT (Table 1). This
was first observed in a small retrospective case series of five children
(one male, four females) with MPS I who ranged in age from 2.3 to
15.3 years at ERT initiation andwho continued onweekly ERT for an av-
erage duration of 3.6 years [28]. Before ERT, mitral valve regurgitation
and aortic valve regurgitation were present in four patients and one pa-
tient, respectively. On treatment, mitral valve regurgitation progressed
in three patients and improved in one patient. The remaining patient
was stable. Aortic regurgitation increased in four patients and stayed sta-
ble in one patient. Similar results were reported in a 6-year follow-up
evaluation of five of the ten MPS I patients originally enrolled in the
phase I/II study of laronidase [29]. Three patients showed an increase
in aortic insufficiency over baseline after 6 years of ERT, while theTable 1
Studies of aortic valve disease outcomes after enzyme replacement therapy in MPS I, II, and VI
Study N MPS Time on treatment at study end Regurgitation at
Median (range) years Increased
Braunlin (2006) [28] 5 I 3.6 (0.3 to 7.3) Mitral: 3/5 (60%)
Aortic: 4/5 (80%)
Sifuentes (2007) [29] 5 I 6 Mitral: 4/5 (80%)
Aortic: 3/5 (60%)
Fesslova (2009) [30] 8 I and II 2.7 (2.0–5.0) 4/8 (50%)
Okuyama (2010) [31] 9 II 1 0/9
Brands (2012) [32] 20 I, II, VI 2.0 (0.9–6.0) 12/20 (60%)
Braunlin (2012) [33] 54 VI 1.8 (96 weeks) Mean aortic regu
from 0.53 ± 0.87
at the end of the
MPS, mucopolysaccharidosis.other two patients maintained stable aortic insufficiency. Mitral valve
regurgitation was stable in four patients and worse in one patient. A
larger MPS cardiac natural history study included nine patients who
were receiving ERT (five patients with MPS I Hurler–Scheie, two with
MPS I Scheie, and two with attenuated MPS II) [30]. Eight of these pa-
tients had available follow-up cardiac data. Of these, four were deter-
mined to have stable cardiac valve disease and four had progressive
valve disease. In a study of idursulfase in treatment-naïve, adult, male
Japanese patients with attenuated disease, all nine patients had abnor-
mal, but stable valve disease after 12 months of weekly treatment
with idursulfase [31]. No improvements were noted.
A recent prospective study of 24 patients with MPS I, II, or VI con-
firms these earlier reports that ERT does not appear to improve valve
disease in most patients [32]. Patients began ERT at a median age of
5.3 years (1–18 years) and received therapy for a median duration of
2.0 (0.9–6.0) years. At baseline, all of the patients had abnormal valves.
Mitral valve regurgitation was seen in seven patients (three MPS I and
four MPS VI), aortic valve regurgitation in seven patients (two MPS I,
three MPS II and two MPS VI), and tricuspid valve and pulmonary
valve regurgitation in two patients (both MPS VI). Complete follow-up
data were available for 20 out of the 24 patients, and of these, increased
valve regurgitation was seen in 12 (60%), stabilization was seen in five
(25%), and improvement was seen in three (15%).
Although overall cardiac function did not improve with ERT in the
above studies, some evidence indicates that younger patients may be
more likely to improve. Braunlin and colleagues conducted a post-hoc
analysis of prospective data from 54 MPS VI patients who underwent
echocardiograms at baseline, at 24–48 weeks, and at 72–96 weeks after
initiation of weekly galsulfase treatment during the phase I/II, phase II,
and phase III trials [33]. The mean age at baseline was 11.8 ± 5.4 years
(range 6–29 years). At baseline, the mean mitral valve gradient was
7.28 ± 5.68 mm Hg (normal: b5 mm Hg), indicating mitral stenosis,
and the mean mitral valve regurgitation score was “mild” at baseline
(1.35 ± 1.05). The mean peak systolic gradient across the aortic valve
was 13.72 ± 10.78 mm Hg (normal: 11–13 mm Hg) at baseline, and
the mean aortic regurgitation score was “trace” (0.53 ± 0.87). After
96 weeks of ERT, the mean mitral valve gradient, the mean aortic valve
gradient, and the mean mitral valve regurgitation score did not change
significantly. Aortic regurgitation, however, did increase significantly, al-
though still within the “trace to mild” category. A subgroup analysis of
patients less than 12 years old versus those 12 years of age or older
found that mitral and aortic valve stenosis and mitral regurgitation did
not change significantly from baseline after 96 weeks of therapy for ei-
ther group. However, the aortic valve regurgitation score did increase sig-
nificantly from baseline in those patients 12 years of age or older
(p = 0.015). The authors speculated that, although the increase in aortic
valve regurgitation score among the older patients was not large enough
to have a physiologic consequence for those patients, it may imply that
cardiac valve pathology, once begun, may not be reversible..












5/20 (25%) 3/20 (15%)
rgitation score increased
at baseline to 0.88 ± 0.99
study (p = 0.004)
Mean mitral regurgitation score
was 1.35 ± 1.05 at baseline and
1.51 ± 0.73 at the end of the study
(p = 0.459)
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There is limited information available about the impact of ERT on
bone disease in the MPS. There is some evidence to suggest that
established dysostosis multiplex typically remains stable and does not
improve appreciably with ERT. In the long-term follow-up of patients
from the phase I/II trial of laronidase, comprehensive skeletal surveys
from baseline through 6 years of treatment did not reveal any distinct
changes in dysostosis multiplex over time, except for one patient with
increased spine and hip disease [29]. An Italian study of 36 patients
with MPS II (mean age 12.6 years, range 2.8–32.2 years) used magnetic
resonance imaging to evaluate brain and spine features, including cranial
bone abnormalities and spinal anomalies, over time [34]. A subset of 15
patients were treatedwith idursulfase, and after amedian treatment du-
ration of 1.6 years (range 1–2.9 years), cranial bone abnormalities and
spinal anomalies remained stable for most patients. Two idursulfase-
treated patients experienced a worsening of intervertebral disc abnor-
malities. The authors concluded that GAG-mediated damages to cranial
bone and spine might be difficult to revert once they have occurred.
A greater amount of data are available about the effects of ERT upon
joint range of motion (JROM) in the MPS. In the phase III trial of
laronidase for MPS I, the mean change in active shoulder flexion, the
only joint studied, did not differ significantly between the treated and
untreated groups [6]. Statistically significant improvements in shoulder
flexion were seen, however, in the open-label extension study, with a
mean change of 17.4° ± 3.6° from baseline [4]. At the end of the exten-
sion study, 17 of 37 patients (46%) had an increase of ≥20° in mean
shoulder flexion, 18 of 37 patients (49%) remained stable (b20° change
in either direction), and 2 of 37 patients (5%) had a decrease of≥20°. No
significant changes were seen for knee flexion. A longer-term, 6-year
follow up of five patients from the original phase I/II study reported
that shoulder extension increased over 6 years, improving by a mean
of 38.7° on the right and by 32.1° on the left at the end of the study
[29]. Tylki-Syzmańska and colleagues conducted a study of motor
movement in 17 treatment-naïve Polish patients with MPS I (10 with
MPS I-Hurler, 2 with MPS I-Hurler/Scheie, and 5 with MPS I-Scheie)
by assessing upper extremity JROM [35]. After 52–208 weeks of ERT
with laronidase, only mean passive shoulder flexion (p = 0.013) im-
proved significantly from baseline. When only data from the subset of
patients with the Hurler/Scheie or Scheie phenotypes was analyzed, ac-
tive should flexion also showed significant improvements from baseline
(p = 0.046). Eight of the patients with the Hurler phenotype in this
study were 1 year old at enrollment. Among these young patients
with the severe phenotype, the authors noted no change or only a slight
increase in JROMover the study, saying that “earlier introduction of ERT
led to slower progression of symptoms”. Unfortunately, no subgroup
analysis for these young patients was published.
In the phase II/III trial of idursulfase for MPS II, passive elbowmobil-
ity, a secondary endpoint, improved in the weekly treated group as
compared with placebo (p = 0.0476), but no other significant changes
in passive JROM were found [12]. The extension study found progres-
sive, statistically significant, and clinically important (≥10%) improve-
ments in JROM for the shoulder [10]. No significant differences in
JROM were observed for the elbow, wrist, digits, hip, knee, or ankle. A
Japanese open-label, 12-month study of idursulfase treatment for 10
adult patients found improved mean shoulder flexion, shoulder abduc-
tion, knee flexion, hip flexion, and elbow extension, but only hip flexion
reached statistical significance (p = 0.031) [31].
The phase III trial galsulfase for MPS VI evaluated JROM as a tertiary
endpoint and found that ERT had no statistically significant effects upon
any joint [7]. Only shoulder JROM data was analyzed in the extension
study, and again, no effect of galsulfase was found.
2.2.3. Airway disease
Pulmonary function measured by %FVC or absolute FVC was shown
to improve in the pivotal trials of laronidase and idursulfase (but not
galsulfase); however, the data suggest that airway disease does notnormalize with treatment [6,7,12]. In the phase III study of laronidase,
the baseline mean %FVC for the laronidase treatment group was
48.4 ± 14.5% [6], but all enrolled patients had a %FVC b80% at baseline
per inclusion criteria. After 26 weeks of treatment, the mean %FVC in-
creased by 5.6% (median, 3.0%). While this improvement is statistically
significant and clinically meaningful [36], the final mean %FVC for the
treated patients was still well below the normal range [37]. In addition,
the gains were not fully maintained, as a small but steady decrease of
0.78 percentage points per year was seen in the 3.5-year extension
study [4]. When individual patient %FVC responses were tabulated in
the extension study, the authors reported improvement in 18% of pa-
tients, a stable value in 55%, and a decline in 28% [4].
The double-blindphase II/III trial of idursulfase found a 3.45 ± 1.77%
increase in %FVC among patients treatedweekly, whichwas not statisti-
cally significant [12]. However, absolute FVC increased by 0.22 ± 0.05 L
from a baseline of 1.19 ± 0.10 L for weekly treated patients in the
double-blind trial, compared with an increase of 0.06 ± 0.03 L from a
baseline of 1.09 ± 0.09 L in the placebo group (p = 0.0011). This im-
provement was further increased by 0.44 ± 0.10 L over the extension
study (D.A.H. Whiteman, personal communication). Given that the
mean age of patients at baseline was approximately 14 years, the final
values after 3.5 to 4 years of idursulfase treatment remained below the
normal range [37]. In a small study of open-label idursulfase treatment
of adult Japanese patients with attenuated MPS II, the mean %FVC was
39.9 ± 6.6%, which increased by 3.8 ± 2.8 percentage points after
1 year [31]. The mean absolute FVC increased by 0.1 ± 0.1 L over the
baseline of 1.4 ± 0.3 L. Neither value reached statistical significance.
The only reported clinical trial data for sleep apnea in patients re-
ceiving ERT comes from the phase III and extension studies of laronidase
[4,6]. In the pivotal trial, the AHI significantly decreased by 6.0 events
per hour among those treated MPS I patients whose baseline AHI was
abnormal (p = 0.014). A final mean reduction of 7.6 ± 4.5 events per
hour was seen in the extension. The actual baseline value for the sub-
group of patients whose AHI suggested sleep apnea was not reported,
so it is difficult to determine if the final value is within normal limits
(AHI ≥10 for ages ≤15 years, AHI ≥15 for ages N15 years); however,
the baseline AHI for all patients was 17.5 ± 15.5 events per hour, mak-
ing it unlikely [4,6].
Some retrospective data for airway disease have also been reported.
A chart review of 17 Australian patients with MPS (four MPS I-Hurler,
ten MPS II, one MPS III, one MPS IV, and one MPS VI) who had received
a total of 141 anesthetics between 1998 and2011 found through a logis-
tic regression analysis that ERT did not reduce the incidence of difficult
airway management [38]. Five out of the ten enrolled MPS II patients
were treated with idursulfase beginning at a mean age of 9.4 years
(range 8–13 years). The odds of a difficult intubation were greater for
treated patients than for those receiving no treatment, although this
was not statistically significant. The authors noted that the use of
idursulfase late in the clinical course when significant deposition of
GAG in the airway had already occurred likely contributed to the appar-
ent lack of effect.
3. The pathophysiology of MPS and treatment limitations
Historically itwas believed that the primary storage of GAG and their
deposition in tissues was solely responsible for the signs and symptoms
associated with theMPS [39], but recent research suggests a more com-
plex picture [40]. (Please see the review articles by Clarke [41] and
Simonaro et al. [42] for an in-depth discussion of this topic.) Far from
inert storage materials, GAG have been described as one of themost bi-
ologically active, information-dense biological molecules [43]. Their
storage appears to lead to the perturbation of cellular, tissue, and
organ homeostasis through secondary pathogenic cascades
[40,41,44–47]. Accumulation of GAG and secondary storagemetabolites
has also been linked with increased excretion of cytokines and inflam-
matory mediators, activation of the inflammatory response, and
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deed, peripheral leukocytes from untreated MPS I and MPS II patients
have significantly elevated levels of lipid peroxidation, carbonyl group
content, and DNA damage, all indicators of severe oxidative damage
[48,49]. Intracellularly, GAG storage can alter the endosomal network,
impacting intracellular targeting pathways, endocytosis, and autophagy
[50–52]. Once activated, these secondary events may not be easily re-
versible. In addition, the presence of excess GAG within lysosomes has
been shown to inhibit lysosomal enzymes that otherwise would func-
tion normally, leading to the secondary storage of a variety of molecules
that may influence pathology [53–56].
3.1. Pathophysiology of cardiac valve disease
Many of the above-mentioned pathological mechanisms may come
into play in a complex clinical feature like cardiac valve disease. First,
there is presumed primary GAG storage in cardiac tissue. Proteoglycans
such as decorin and biglycan contain dermatan sulfate, which are stored
in MPS I, II, and VI; these proteoglycans are normally found in apprecia-
ble quantities in cardiac valve tissue [57]. In the MPS, GAG levels are el-
evated, and histopathological and electron microscopy (EM) studies
have revealed the infiltration of GAG-loaded “clear” cells and granular
cells within cardiac valves (leaflets, annuli and chordae tendineae), en-
docardium, myocardial walls, coronary arteries, aorta and the conduc-
tion system [58,59]. The “clear” cells appear to be activated valvular
interstitial cells [60]. Such cells normally are engaged inmaintaining val-
vular structural integrity and mediating response to injury [61], but in
patients with MPS, they appear to be engaged in attempted, but ineffec-
tive, valve repair [60]. It has been hypothesized that these cells may
reach an activated state due to the accumulation of GAG and a resulting
stimulation of the lipopolysaccharide signaling pathway. GAG stimula-
tion of the lipopolysaccharide signaling pathway may result in the re-
lease of proinflammatory cytokines and matrix metalloproteinases.
This hypothesis is supported by thefinding that the activated valvular in-
terstitial cells stain positively formatrixmetalloproteinase 9 (MMP9), an
enzyme responsible for degradation of proteoglycans in the extracellular
matrix. Upregulation of MMP9 in cardiac valve tissue has been associat-
ed with inflammation and pathological extracellular matrix remodeling,
leading to valve regurgitation and stenosis [62].
Autopsy reports from patients with MPS I confirm that ERT does not
fully clear GAG from all cardiac tissue types once cardiac disease is evi-
dent [63,64]. Postmortem findings in a 3.5-year-old boywithMPS I who
had received laronidase treatment for 1 year revealed hypertrophic car-
diomyopathy, severe aortic valve and mitral valve thickening with
shortened chordae, and endocardial fibroelastosis [64]. Numerous his-
tiocyteswith enlarged lysosomeswere seen in the thickened endocardi-
um tissue on EM analysis. By contrast, EM examination of the liver and
the cardiac muscle revealed no accumulation of GAG. An autopsy of a
20-year-old male with MPS I who had been receiving laronidase treat-
ment for 104 weeks revealed a thickened tricuspid valve, thickened
and rigid aortic, mitral, and pulmonary valves, and GAG deposition in
the heart valves and endocardium.
3.2. Pathophysiology of skeletal and connective tissue disease
As with cardiac valve disease, established dysostosis multiplex and
abnormal joint range of motion seem to stabilize or progress on long-
term ERT, but generally do not improve. Many features of dysostosis
multiplex, such as thoracolumbar kyphosis/scoliosis, odontoid hypopla-
sia, wide oar-shaped ribs, shortened long bones, coxa valga, dysplastic
femoral heads, genu valgum, and bullet-shaped phalanges, are in part
due to abnormal endochondral ossification. Chondrocytes in the resting
zone of the growth plates of patients withMPS I, II and IV have been re-
ported to be overly large and to contain undegraded GAG. These
chondrocytes appear to interrupt the architecture of the growth plate
such that the resting zone is abnormally large [65]. GAG have beenpostulated to play a role in this process through the binding of mitotic
growth factors and interruption of cellular signaling [66]. The ossifica-
tion zone of the growth plate also seems to be affected. In MPS I mice,
ossification starts before the GAG have been removed from the cartilage
extracellular matrix; thus, remnants of cartilage remain in the newly
formed bone, leading to growth retardation and bone malformation
[67]. It follows that even if the levels of stored GAG are reduced by
ERT, disruptions in the growth plate and remnants of cartilage within
bone are not likely to be corrected once they have been established.
Progressive decreased joint range of motion is a common feature in
MPS I, II and VI. Inflammation has been shown to play a critical role in
the joint and articular cartilage disease in MPS animals [68]. Simonaro
and colleaguesfirst reported inMPSVI animal that articular chondrocytes
undergo a high rate of apoptosis and release nitric oxide and inflammato-
ry cytokines [69]. The accumulation of GAG results in an activation of a
specific toll-like receptor (TLR4) which leads to an inflammatory cascade
due to the release of TNF-alpha and other inflammatory cytokines from
chondrocytes [70]. The subsequent increased chondrocyte apoptosis
and the release of matrix metalloproteinase contribute to the joint de-
struction and abnormal function [71].
3.3. Pathophysiology of airway disease
Airway involvement in theMPS includes upper airway disease, lower
airway disease, and restrictive lung disease [72,73]. In the upper airway,
narrowed or blocked nasal passages, macroglossia, decreased jaw range
of motion, enlarged adenoids and tonsils and increased redundant
(folds) supraglottic tissues can lead to obstructive sleep apnea [73,74].
Lower airway disease is primarily caused by tracheomalacia and the
narrowing of the tracheal caliber that develop over time due to infiltra-
tion of the submucosa and tracheal cartilage with GAG [75,76]. Restric-
tive lung disease is caused by inefficient mechanical properties of the
chest secondary to skeletal abnormalities. The antero-posterior diameter
of the chest may be increased placing the ribs in a more horizontal posi-
tion. Widened “oar shaped” ribs, a short thorax, kyphosis, scoliosis, or
kyphoscoliosis are common. Further limitationsmay be caused by eleva-
tion of the diaphragm due to hepatosplenomegaly [77].
Although the clinical features associated with upper airway disease
in MPS, such as narrowed or blocked nasal passages, macroglossia, in-
creased redundant supraglottic tissues and enlarged adenoids and ton-
sils, may improve with ERT, tracheal abnormalities appear to persist.
MPS VI rat studies have confirmed that ERT treatment is associated
with improvements in mean tracheal cross-section area in treated ani-
mals as compared with controls, but normalization does not occur
[71]. The skeletal abnormalities contributing to restrictive lung disease
generally do not improve with ERT.
4. Summary: the benefits and limitations of ERT for the MPS
ERT for MPS I, II, and VI may produce improvements in walking abil-
ity, endurance, and pulmonary function as evidenced by the pivotal tri-
als and extension studies. Cardiac valve disease, JROM, and skeletal
disease, on the other hand, do not generally seem to improve with
ERT if pathological changes are already presentwhen ERT is started. Air-
way disease improves, but usually does not normalize. An appreciation
of the pathophysiology of the MPS and the multi-faceted role of GAG in
the bodymakes it clear that primaryGAG storage is not fully responsible
for all of the disease features. Disruption of GAG catabolism has far-
reaching consequences both intracellularly and extracellularly due to
the triggering of secondary pathogenic cascades. It appears that many
of the consequences of these secondary pathogenic cascades, while
they may improve, cannot be fully corrected even with long-term ERT.
Further studies of ERT in younger patients or in patients without clini-
cally significant somatic disease at baseline are warranted to determine
if ERT can prevent the onset of disease features, thereby dramatically al-
tering the natural history of the disease.
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TheMPS are progressive heterogeneous lysosomal storage disorders
with early morbidity and premature mortality. The cardiac, pulmonary,
and musculoskeletal systems are the major contributors to the somatic
clinical burden in patients with MPS. The development and availability
of IV ERT has resulted in clinical improvement, but current usage has
not realized the full potential of this therapy. The long-term outcomes
of MPS patients receiving IV ERT have demonstrated that many disease
manifestations are not reversible and that prevention should be the ex-
pectation. The concept that improved clinical outcomes can be achieved
by starting ERT early is supported by the observation that lysosomal
GAG storage occurs prenatally, animal studies showing improved
outcomes with very early treatment, clinical studies in young patients
demonstrating an acceptable safety profile, case reports showing the
benefit of early versus later treatment in siblings, and personal clinical
experience.Fig. 1. (A to I) Effects of intravenous laronidase from birth on skeletal abnormalities in MPS I d
treated (0.58 mg/kg) MPS I-affected canines (G to I), and untreated MPS I-affected canines (J to
seen in an untreated 17-month-old animal (J). (K) Severe narrowing of the intervertebral disc sp
a weekly treated dog (0.58 mg/kg) (H), not seen in (B), a normal dog, or (E) a treated dog (1
(L) Toe splaying seen in untreated animal, but not seen in normal or treated dogs (C, F, and I).
Reproduced from Dierenfeld AD, McEntee MF, Vogler CA, et al. Replacing the enzyme alpha-L-
mucopolysaccharidosis type I. Sci Transl Med. 2010;2(60):60ra89.Enzyme replacement therapies for MPS I, II and VI were approved
based on double-blinded clinical trials in which clinically meaningful
somatic improvements occurred. The patients enrolled were 5 years
and older, were intellectually intact, and had significant somatic dis-
ease at the onset of treatment. From these trials and other data de-
scribed above, it is clear that ERT in established disease does not
result in normalization/correction of somatic disease, but at best re-
sults in some improvements in certain disease manifestations, with
stabilization to slow deterioration in others.
The progressive nature of the MPS disorders suggests that ERT
should be initiated as soon as possible after diagnosis—perhaps even be-
fore obvious clinical features are apparent. Indeed, studies of tissues
from affected aborted fetuses have demonstrated that GAG storage be-
gins prenatally. Using EM, GAG storage was seen in the mesenchymal
cells of the liver and spleen and neurons of the spinal ganglia, spinal
cord, and brain from a 22-week-old fetus with MPS II [78]. Another
group examined tissues from four fetuses aged 18–30 weeks gestationogs. Radiographs of normal (A to C), treated (1.57 mg/kg) MPS I-affected canines (D to F),
L). C3, third cervical vertebra (B, E, H, and K). A physeal remnant/open physis (circled) is
ace (circled) in an untreated, affected dog andmoderate intervertebral space narrowing in
.57 mg/kg per week). Also evident in (K) is C2–C3 narrowing of the intervertebral space.
iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with
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uoles in hepatocytes, Kupffer cells, splenic reticulo-histiocytic cells, pa-
rietal cells of Bowman's capsule, heart valves, fibroblasts, endothelial
and smooth muscle cells, chondrocytes, and cells of the peripheral and
central nervous system [79].
Several studies have investigated whether outcomes improve when
ERT is begun from birth in animal models of MPS I and VI. For MPS I, in-
travenous (IV) laronidase treatment (either 0.58 mg/kg or 1.57 mg/kg
weekly) was initiated in affected model dogs between 3 and 23 days
of age and was continued for 56 to 81 weeks [80]. At the end of the
study, the GAG levels in the liver, spleen, lung, myocardium, renal cor-
tex, and renal medulla were at or below the normal range of values in
all treated dogs, and liver size was normal. Of note, cardiac valvular
GAG content and mean anterior mitral leaflet thickness were normal
in all treated animals. Skeletal abnormalities were reduced in the low-Fig. 2. Scoliosis in the older affected sister (left) of the sibling pairwithMPS I at 3.6 years of age. S
Sibling 1 had not received laronidase at this time, while Sibling 2 had received 182 weeks of la
Reproduced fromMcGill JJ, Inwood AC, ComanDJ, LipkeML, de Lore D, Swiedler SJ, et al. Enzyme
study. Clin Genet 2010;77:492–8.dose group of treated dogs and were nearly completely prevented in
the high-dose group of treated dogs (Fig. 1). Similar results have been
reported for MPS VI cats who initiated ERT between 14 and 58 h after
birth and continued on weekly treatment for 5, 6 or 11 months [81].
Treated cats had improved bone quality, density, and dimensions, and
GAG storage in heart valves was nearly normal. Recent studies in the
MPS I mouse have demonstrated that IV ERT started at birth compared
to two months of age improves outcome in difficult-to-treat organs,
such as aorta and heart valves [82].
Sibling case studies from human patients report similar findings
documenting the benefits of early treatment in patients with MPS. In
MPS I, a 5-month-old boy who was pre-symptomatic began laronidase
after diagnosis at 3 days of age. His older sister was diagnosed with
MPS I Hurler–Scheie at 4.5 years of age. After 5 years of ERT, the boy
displayed no signs of coarse facies, joint disease, organomegaly, cardiacibling 1 and Sibling 2 are both affectedwithMPS I and are both pictured at 3.6 years of age.
ronidase after being diagnosed prenatally.
replacement therapy formucopolysaccharidosis VI from 8 weeks of age—a sibling control
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stable corneal clouding. The older sister at 4 years of age experienced
joint stiffness, thick skin, corneal clouding, hepatosplenomegaly, mod-
erate mitral insufficiency with thickened valve leaflets and anterior
edge prolapse,mild left atrium thickening, dysostosismultiplex, and ob-
structive hydrocephalus which required shunting [83]. A similar case
study has been published for MPS VI in which two affected siblings
were compared at the age of 3.6 years. The older sister had not received
ERT at that age; the younger brother was diagnosed prenatally and was
started on ERT at 8 weeks of age. At the age of 3.6 years, the older sister
presented with scoliosis (32° and fixed; Fig. 2), short stature, moderate
joint restriction in most joints, claw hands, mild mitral valve incompe-
tence, hepatomegaly, and coarse facies. At the same age, but after
182 weeks of ERT, the younger brother presented with no scoliosis
(Fig. 2), normal stature, mild joint restriction in shoulder only, normal
hands, normal cardiac features, normal liver and spleen size, and normal
facial appearance [84]. For MPS II, a sibling case report was published in
which an affected boy was treated with ERT from 3 months of age [85].
After 3 years of treatment, the only somatic sign of the disease was a
mild deformity of one vertebra. No other disease features were found.
This boy was diagnosed very early because of an older, affected sister
who began ERT at 7.5 years of age. Unlike her younger brother, her dis-
ease continued on a severe progressive course despite 3 years of ERT. A
more traditional sibling case study was recently published for MPS II,
with similar findings. Two Japanese brothers with MPS II caused by a
complex rearrangement between the IDS gene and the IDS-2
psuedogene were followed [86]. The older brother began treatment
with idursulfase at 3.0 years of age, while the younger sibling started
treatment at 4 months of age. At the start of treatment, the older broth-
er showed typical somatic features of MPS II, including mitral valve re-
gurgitation, gibbus deformity, joint stiffness, umbilical hernia, coarse
facies, short stature, hepatomegaly, and cognitive impairment. After
2 years of treatment, the older brother's somatic disease was stable or
improved, while the cognitive decline continued. After 32 months of
ERT (age 3.0 years), the younger brother remained free from most of
the somatic features that had already appeared in his brother at the
same age. His only apparent disease manifestations were otitis media
with effusion, mild dysostosis multiplex, and mild cognitive
impairment.
Although safety has been a concern with very young patients, the
clinical trial inMPS I patients under the age of 5 years has demonstrated
that laronidase produces somatic improvements, with no new safety
concerns. A similar study has been conducted for MPS II on the use of
idursulfase in children under 7 years old (NCT00607386). The authors
reported similar effects of ERT upon uGAG levels and liver and spleen
size as have been previously reported for older patients, with no new
safety concerns found [23]. A review of the clinical experience of MPS
II patients under the age of 5 years in the Hunter Outcome Survey [87]
also reported reductions in uGAG concentration and decreased liver
and spleen size with ERT, with no new safety concerns noted in this
younger population [11,88].
In summary, many lines of evidence, albeit with limited data, sup-
port my opinion that treatment of patients with MPS should occur
early, at least at the onset of clinical disease and most likely pre-
symptomatically (before onset of significant clinical disease) to obtain
better long-term outcomes. Lysosomal storage has been demonstrated
to occur in affectedMPS fetuses prior to 30 weeks gestation, supporting
early initiation of ERT. The animal data aremore compelling and suggest
that early treatment can prevent the progression of some of the clinical
disease features that occur in MPS. The handful of sibling case study re-
ports demonstrating rather remarkable outcomes in the younger sib-
lings treated from shortly after birth, with no new safety concerns
seen, further support the animal study data. Certainly there are no
data whatsoever to suggest that waiting to treat results in a better out-
come for this population, while there are some data and clinical experi-
ence to support commencing ERT as soon as possible.With this inmind,I support the use of ERT in pre-symptomatic infants with a confirmed
diagnosis of MPS as a treatment option, given that, in my opinion, IV
ERT is much better at preventing than correcting clinical disease in
MPS. A strong need for further clinical trials in this area remains.
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